Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company based around a unique drug delivery platform originally developed by Monash University researchers Professor Christopher Porter and his team at the Monash Institute of Pharmaceutical Sciences (MIPS). Using the proprietary GlyphTM platform, Seaport Therapeutics is advancing a clinical stage pipeline of neuropsychiatric medicines in areas of high unmet patient needs including depression and anxiety disorders. Seaport Therapeutics is a spinout of PureTech.

Lead Researcher: Christopher Porter
Website: seaporttx.com